Compare RDHL & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDHL | SGLY |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.4M |
| IPO Year | 2012 | 2008 |
| Metric | RDHL | SGLY |
|---|---|---|
| Price | $0.58 | $6.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.7K | ★ 296.8K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,813,193.00 |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.18 |
| 52 Week High | $2.79 | $8.55 |
| Indicator | RDHL | SGLY |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 67.64 |
| Support Level | N/A | $0.38 |
| Resistance Level | $0.76 | N/A |
| Average True Range (ATR) | 0.06 | 1.12 |
| MACD | -0.00 | 0.35 |
| Stochastic Oscillator | 14.46 | 70.46 |
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.